Use of concentrated insulin human regular (U-500) for patients with diabetes

American Journal of Health-System Pharmacy

Volumn 67, Issue 18, 2010, Pages 1526-1535

  Segal, Alissa R ^a,b   Brunner, Jack E ^c   Burch, F Taylor ^d   Jackson, Jeffrey A ^d,e  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b JOSLIN DIABETES CENTER   (United States)

^c Endocrine and Diabetes Care Center   (United States)

^d Lilly USA   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Dosage; Drug administration; Errors, medication; Hypoglycemia; Insulin human; Insulins; Obesity; Pharmacodynamics; Pharmacokinetics; Toxicity

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; NEUTRAL INSULIN; PIG INSULIN; U 500; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE ABSCESS; INJECTION SITE DISCOMFORT; INJECTION SITE INFECTION; INSULIN RESISTANCE; MEDICATION ERROR; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; CLINICAL PRACTICE; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MEDICATION ERRORS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 78650884395     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090554     Document Type: Review

References (55)

1. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: Centers for Disease Control and Prevention; 2008.
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008; 31:596-615.
3. Lane WS, Cochran EK, Jackson JA et al. High dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009; 15:71-9.
4. Musso C, Cochran E, Moran SA et al. Clinical course of genetic diseases of the insulin receptor (Type A and Rabson- Mendenhall syndromes): a 30-year prospective. Medicine. 2004; 83:209-22. (Pubitemid 38955444)
5. Musso C, Cochran E, Javor E et al. The long term effect of recombinant methionyl human leptin (r-metHuLeptin) therapy on hyperandrogenism and menstrual dysfunction in male and female hypoleptinemic lipodystrophic patients. Metabolism. 2005; 54:255-63 (Pubitemid 40174856)
6. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350: 1220-34. (Pubitemid 38339366)
7. Rooney DP, Ryan MF. Diabetes and partial lipodystrophy following sclerodermatous chronic graft vs. host disease. Diabet Med. 2006; 23:436-40.
8. Arioglu E, Andewelt A, Diabo C et al. Clinical course of the syndrome of auto-antibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine. 2002; 81:87-100. (Pubitemid 34218566)
9. U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53.
10. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86.
11. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353:2643-53.
12. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359:1577-89.
13. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193-203.
14. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 2009; 32(suppl 1):S13-61.
15. Binder C. Absorption of injected insulin. Acta Pharmacol Toxicol. 1969; 27(suppl 2):1-84.
16. Data on file. IMS Health National Prescription Audit Monthly, July 2005-July 2009. Eli Lilly and Company, Indianapolis.
17. Galloway JA, Spradlin CT, Nelson RL et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981; 4:366-76. (Pubitemid 12201586)
18. Binder C, Lauritzen T, Faber O et al. Insulin pharmacokinetics. Diabetes Care. 1984; 7:188-99. (Pubitemid 14137203)
19. Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspension in pigs. Diabetes Res Clin Pract. 2000; 50:161-7.
20. Khan M, Lee YY. The pharmacokinetic and pharmacodynamic properties of regular U-500 insulin in healthy subjects. Diabetes. 2007; 56(suppl):1294-P. Abstract.
21. Khan MI, Sarabu B. The pharmacokinetic and pharmacodynamic properties of regular U-500 insulin in healthy obese subjects. Diabetes. 2009; 58(suppl 1):2333-PO. Abstract.
22. Barnett AH. How well do rapid-acting insulins work in obese individuals? Diabetes Obes Metab. 2006; 8:388-95. (Pubitemid 44349230)
23. Eli Lilly and Company. Initiated clinical trials. www.lillytrials.com/ initiated/ files/12774.pdf (accessed 2010 Jun 21).
24. Knee TS, Seidensticker DF, Walton JL et al. A novel use of U-500 insulin for continuous insulin infusion in patients with insulin resistance: a case series. Endocr Pract. 2003; 9:181-6.
25. Garg R, Lawrence IG, Akinsola MO et al. Improved glycaemic control in severely insulin resistant, insulin-treated diabetic patients with U500 Actrapid over two year follow-up. Diabetologia. 2004; 47(suppl 1):149. Abstract.
26. Neal JM. Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy. Endocr Pract. 2005; 11:305-7.
27. Wafa WS, Khan MI. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care. 2006; 29:2175-6. Letter.
28. Lane WS. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract. 2006; 12:251-6.
29. Nayyar V, Lawrence I, Kong MF et al. Long-term follow-up of patients on U-500 human Actrapid. Diabetologia. 2007; 50(suppl 1):S395. Abstract.
30. Bulchandani DG, Konrady T, Hamburg MS. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract. 2007; 13:721-5.
31. Ballani P, Tran MT, Navar MD et al. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care. 2006; 29:2504-5. [Erratum, Diabetes Care. 2007; 30:455.]
32. Garg R, Lawrence IG, Davies MJ et al. Improved glycaemic control with short term use of U-500 insulin in poorly-controlled patients with type 2 diabetes mellitus is maintained for up to 3.5 years with conventional insulin regimens: a prospective observational follow up study. Diabetes. 2006; 55(suppl):297-P. Abstract.
33. Garg R, Johnston V, McNally PG et al. U-500 insulin: why, when, and how to use in clinical practice. Diabetes Metab Res Rev. 2007; 23:265-8. (Pubitemid 46851466)
34. Hatipoglu B, Soni S, Espinosa V. Glycemic control with continuous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient. Endocr Pract. 2006; 12:542-4. (Pubitemid 46456042)
35. Evans KM, Millward BA. Marked insulin resistance in pregnancy. Pract Diab Int. 2006; 23:115-7. (Pubitemid 44755508)
36. Dolberg BK, Lenhard MJ. Successful outcome of pregnancy in a patient with generalized lipoatrophic diabetes mellitus. Endocr Pract. 2000; 6:34-6.
37. Kahn CR, Flier JS, Bar RS et al. The syndromes of insulin resistance and acanthosis nigricans: insulin-receptor disorders in man. N Engl J Med. 1976; 294:739-45.
38. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005; 28:1240-4. [Erratum, Diabetes Care. 2007; 30:1035.]
39. Cochran E, Gorden P. Use of U-500 insulin in the treatment of severe insulin resistance. Insulin. 2008; 3:211-8.
40. Food and Drug Administration. Potential signals of serious risks/new safety information identified from the Adverse Event Reporting System (AERS) between January-March 2008. www.fda.gov/ Drugs/GuidanceComplianceRegulatory Information/Surveillance/AdverseDrug Effects/ucm085914.htm (accessed 2009 Jul 12).
41. CIOMS Working Groups III and V. Frequency of adverse drug reactions. Guidelines for preparing core clinical-safety information on drugs. 2nd ed. Geneva: Council for International Organizations of Medical Sciences; 1999:36.
42. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001; 24:758-67. (Pubitemid 32888861)
43. Rosenstock J, Ahmann AJ, Colon G et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/ lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008; 31:20-5.
44. Hundia V, Pettit A, Egerton J. Infusion site infection in a patient using U-500 insulin delivered via insulin pump. Pract Diab Int. 2007; 24:489.
45. Ross SA, Jamal R, Leiter LA et al. Evaluation of 8 mm insulin pen needles in people with type 1 and type 2 diabetes. Pract Diab Int. 1999; 16:145-8. (Pubitemid 29410623)
46. Schwartz S, Hassman D, Shelmet J et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004; 26:1663-78. (Pubitemid 39643027)
47. Tomky DM, Kulkarni K. Intensifying insulin therapy: multiple daily injections to pump therapy. In: Mensing C, ed. The art and science of diabetes self-management education. Chicago: American Association of Diabetes Educators; 2006:371-98.
48. Cohen MR. ISMP medication error report analysis: extra caution needed with U-500 regular insulin. Hosp Pharm. 2001; 36:616.
49. Cooppan R. Acute complications. In: Beaser RS, ed. Joslin's diabetes deskbook: a guide for primary care providers. 2nd ed. Boston: Joslin Diabetes Center; 2007:403-28.
50. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res. 1998; 6(suppl 2):51S-209S. [Erratum, Obes Res. 1998; 6:464.]
51. Laffel L. Sick-day management in type 1 diabetes. Endocrinol Metab Clin North Am. 2000; 29:707-23. (Pubitemid 32016686)
52. Joint Commission. National Patient Safety Goal: identify and, at a minimum, annually review a list of look-alike/ sound-alike drugs used in the organization, and take action to prevent errors involving the interchange of these drugs. www.jointcommission.org/NR/ rdonlyres/C92AAB3F-A9BD-431C-8628- 11DD2D1D53CC/0/LASA.pdf (accessed 2009 Sep 8).
53. ISMP Canada. Insulin errors. ISMP Can Saf Bull. 2003; 3(4):1-2.
54. Hellman R. A systems approach to reducing errors in insulin therapy in the inpatient setting. Endocr Pract. 2004; 10(suppl 2):100-8.
55. Cohen MR, Smetzer JL. ISMP medication error report analysis: insulin concentrate U-500. Hosp Pharm. 2007; 42:887.